Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ)
Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ)
复制标题
日本幼年特发性关节炎相关葡萄膜炎的临床特征和特点：日本儿科风湿病协会（PRAJ）的首次报告
DOI：
10.1186/s12969-019-0318-5
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
M. Mori
中科院分区：
文献类型：
--
作者：
Junko Yasumura;M. Yashiro;N. Okamoto;Kosuke Shabana;H. Umebayashi;N. Iwata;Yuka Okura;Tomohiro Kubota;M. Shimizu;M. Tomiita;Y. Nakagishi;K. Nishimura;Ryoki Hara;M. Mizuta;T. Yasumi;Fumiya Yamaide;H. Wakiguchi;Masao Kobayashi;M. Mori
研究背景虽然在世界各国，特别是欧洲和北美，有许多关于青少年特发性关节炎相关葡萄膜炎（JIA-U）的报道，但亚洲的报道很少。我们的目的是调查JIA-U在Japanes.MethodsData的流行病学，特征和预测因素，回顾性收集了726例JIA患者的病历，截至2016年4月，在15个医疗中心专门从事儿科风湿性疾病。其中，葡萄膜炎患者进行了进一步调查，这种implication.ResultsThe葡萄膜炎的患病率为6.1%，在726 JIA患者检查的具体特点。葡萄膜炎的发病率在关节炎发作较早的患者中显著较高（2.6-vs. 5.8年，P < 0.0001），少关节炎（16.1%-vs. 1.6%，P < 0.001）或抗核抗体。相反，它在类风湿因子或抗环瓜氨酸肽抗体患者中明显不常见。甲氨蝶呤（MTX）、英夫利昔单抗或阿达木单抗使用史也与葡萄膜炎发生相关。葡萄膜炎诊断的中位年龄为5岁，从关节炎发作到葡萄膜炎诊断的中位时间为2年。前葡萄膜炎和双侧葡萄膜炎的发生率分别为79.3%和53.7%。58.5%的病例在葡萄膜炎诊断时无症状。葡萄膜炎诊断与末次观察之间的并发症从31.7%增加到56.1%，特别是白内障增加了3倍。虽然没有患者丧失视力，但61.9%的患者未恢复正常视力（≥ 1.0），并且在许多情况下，活动性葡萄膜炎持续存在，尤其是在男性中。除了类固醇滴眼液（97.6%）和甲氨蝶呤（15.4%），生物制剂用于治疗葡萄膜炎的patients.ConclusionsThe流行病学，特点和预测JIA-U在日本这里描述的第一次。尽管日本JIA-U的患病率低于主要为白人的队列，但据北美和欧洲报道，流行病学，特征和预测因素相似。
BackgroundAlthough there are many reports on Juvenile Idiopathic arthritis-associated uveitis (JIA-U) from various countries, especially from Europe and North America, there are few reports from Asia. Our aim was to investigate the epidemiology, characteristics and predictors of JIA-U in Japan.MethodsData were retrospectively collected on 726 patients with JIA from medical records as of April 2016 at 15 medical centers specialized in pediatric rheumatic diseases. Of these, patients with uveitis were further investigated for the specific characteristics of this manifestation.ResultsThe prevalence of uveitis was 6.1% in the 726 JIA patients examined. Incidence of uveitis was significantly higher in patients with an earlier arthritis onset (2.6-vs.-5.8 years, P < 0.0001), oligoarthritis (16.1%-vs.-1.6%, P < 0.001), or anti-nuclear antibodies. On the contrary, it was significantly less common in patients with rheumatoid factor or anti-cyclic citrullinated peptide antibodies. A history of using methotrexate (MTX), infliximab or adalimumab was also associated with uveitis occurrence. The median age at uveitis diagnosis was 5 years, and the median time from arthritis onset to uveitis diagnosis was 2 years. The occurrence of anterior and bilateral uveitis was 79.3 and 53.7%, respectively. There were no symptoms at uveitis diagnosis in 58.5% of cases. Complications arising between the time of uveitis diagnosis and the last observation increased from 31.7 to 56.1%; in particular, cataract was increased 3-fold. While no patients lost their vision, 61.9% did not recover normal vision (≥ 1.0), and in many cases active uveitis persisted, especially in males. In addition to steroid eye drops (97.6%) and MTX (15.4%), biological agents were used for treating the uveitis in 41.5% of patients.ConclusionsThe epidemiology, characteristics and predictors of JIA-U in Japan are described here for the first time. Although the prevalence of JIA-U in Japan is lower than in predominantly Caucasian cohorts, as reported from North America and Europe, the epidemiology, characteristics and predictors were found to be similar.